Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system
This study comprehensively reviews the safety profile of Tislelizumab, thereby providing clinicians with crucial safety information for prescribing this drug. Due to its relatively low risk of immune-related adverse events (irAEs), Tislelizumab may serve as a promising candidate for combination therapy with other immune checkpoint inhibitors (ICIs). Novel combination strategies involving Tislelizumab and other ICIs are anticipated to provide new therapeutic opportunities for patients experiencing irAEs.
Authors
- Yi Ding (ORCID: https://orcid.org/0000-0003-3968-8490)
- Chen Li (ORCID: https://orcid.org/0000-0002-9366-0993)
- Bai Liu (ORCID: https://orcid.org/0009-0003-5909-4988)
- Xiufeng Wang (ORCID: https://orcid.org/0000-0002-9557-049X)
- Shanshan Cai (ORCID: https://orcid.org/0000-0003-0117-5171)
Institutions
- Shanxi Medical University (CN)
- Zhuhai People's Hospital (CN)
- Second Affiliated Hospital of Jilin University (CN)
- Luliang University (CN)
- Lancaster University (GB)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-26
- DOI
- https://doi.org/10.3389/fimmu.2025.1596842
- Citations
- 4
- Primary Topic
- Pharmaceutical industry and healthcare
- Type
- article
- Field-Weighted Citation Impact
- 6.23
Funders
- U.S. Food and Drug Administration